Increase in the geriatric and pediatric patients is escalating the growth of the sugar-based excipients pharmaceuticals market
Sugar-based
excipients are chemical substances that replace sugar with another substance,
which serves as a vehicle for transporting a medicinal or therapeutic
ingredient. Sugar-based pharmaceuticals are widely used for the treatment of
diabetes and to prevent the absorption of glucose from the gastrointestinal
tract into the bloodstream. Common sugar-based pharmaceuticals are lactose,
glycerin, propionyl, and glycine. They are commonly used in topical gels, lip
balms, cough syrup, oral supplements, vaginal suppositories, intravenous
medications, oral supplements, nasal sprays, oral antibiotics, topical
analgesics, and intravenous fluids. The sugar-based pharmaceutical is also
utilized for the absorption of estrogen by the body and it’s binding with
progestin for the prevention of uterine cancer.
The
increasing use of co-processed excipients in the pharmaceutical industry is augmenting
the growth of sugar-based excipients market. The rise in a number of geriatric
and pediatric patients is again driving the growth of the market. This is
creating demand for a wide-range of syrups and tablets is also projected to
propel the growth of the sugar-based excipients market. Sugar-based excipients
are majorly used in the manufacturing of antibiotics and syrup formulation.
Growing demand for various tablets such as vitamins and many tablets for
pediatric use that contain almost 50% sugar is again expected to foster the
growth of the market. The rapidly growing generic sector due to patent expiry
is further projected to foster the growth of the sugar-based excipients market.
North
America is projected to gain significant growth over the forecast period and
this is attributed to the increasing pharmaceutical industry in the region due
to growing spending by regional players and government. According to the Pharmapproach
Limited, the United States in 2018 was the largest pharmaceutical market,
generating about $484.8 billion which represented 40.4% of the $1.2 trillion
generated worldwide. This was over $350 billion more than any other country.
Also, increasing consumer spending on medicine is further projected to propel
the regional market growth. It is projected that by 2023, Americans would spend
between $635 and $655 billion on medicine.
Key Developments:
1. 1. In October 2020, MEGGLE Excipients
& Technology (MEGGLE) has developed Reta M®. The first
hypromellose/mannitol-based, co-processed excipient specifically designed for
direct compression (DC) and dry granulation of modified release formulations
for the pharmaceutical and nutraceutical market
2. 2. In January 2018, Colorcon Inc.
announces the development of sugar-coated pharmaceutical tablets with the
launch of Opadry® SGR, Rapid Sugar Film Coating System. This new aqueous system
delivers a more streamlined application process
Comments
Post a Comment